OncoMatch/Clinical Trials/NCT05476432
HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
Is NCT05476432 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including FOLFOX 2d and FOLFOX 1d for hepatocellular carcinoma.
Treatment: FOLFOX 2d · FOLFOX 1d — Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin\&5-fluorouracil was effective in unresectable hepatocellular carcinoma (HCC). The program of FOLFOX-HAIC in HCC was performed for 1 day (HAIC 1d) or 2 days (HAIC 2d). We hereby retrospectively compared the efficacy and safety between these two treatment regimens, and explored the predictive power of thymidylate synthase (TYMS), an enzyme involved in the DNA synthesis process and metabolism of fluorouracil. Patients with HCC staged BCLC A-B receive HAIC only, and patients with HCC staged BCLC C receive HAIC plus systemic treatment, such as sorafenib, A+T, lenvatinib.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC A, BCLC B, BCLC C (Barcelona Clinic Liver Cancer)
simultaneously staged as BCLC A, BCLC B or BCLC C based on Barcelona Clinic Liver Cancer staging system. Diagnosed as unresectable with consensus by the panel of liver surgery experts
Lab requirements
Blood counts
platelet count ≥ 75,000/μl; hemoglobin ≥ 8.5 g/dl; absolute neutrophil count (anc) >1,500/mm3; inr > 2.3 or pt/aptt within normal limits
Kidney function
serum creatinine ≤ 1.5 x upper limit of normal
Liver function
total bilirubin ≤ 30mmol/l; serum albumin ≥ 32 g/l; asl and ast ≤ 6 x upper limit of normal; no cirrhosis or cirrhotic status of child-pugh class a only
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify